SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-025933
Filing Date
2022-05-12
Accepted
2022-05-12 16:05:24
Documents
15
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea159803-8k_jasperthera.htm   iXBRL 8-K 31114
2 PRESS RELEASE, DATED MAY 12, 2022 ea159803ex99-1_jasperthera.htm EX-99.1 58327
7 GRAPHIC ex99-1_001.jpg GRAPHIC 4895
  Complete submission text file 0001213900-22-025933.txt   329002

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20220512.xsd EX-101.SCH 3939
4 XBRL DEFINITION FILE jspr-20220512_def.xml EX-101.DEF 27095
5 XBRL LABEL FILE jspr-20220512_lab.xml EX-101.LAB 37343
6 XBRL PRESENTATION FILE jspr-20220512_pre.xml EX-101.PRE 25717
9 EXTRACTED XBRL INSTANCE DOCUMENT ea159803-8k_jasperthera_htm.xml XML 5883
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 22917726
SIC: 2836 Biological Products, (No Diagnostic Substances)